Jarl Ulf Jungnelius
Board member
Pharmaceuticals
Oncopeptides
Sweden
Biography
Jarl Ulf Jungnelius was appointed to the board of Oncopeptides in April 2011. Ulf is a licensed medical practitioner and a specialist in a number of areas including oncology. He has published a number of scientific articles and has more than 25 years’ experience in leadership positions in both large academic and corporate institutions. He has been instrumental in the development and registration of gemcitabine (Gemzar), premetrexed (Alimta), Sunitinib (Sutent), lenalidomide (Revlimid) and the albumin bound nanoparticle paclitaxel (Abraxane).
Research Interest
life sciences businesses
